TELO - NASDAQ

Telomir Pharmaceuticals, Inc. Common Stock

TELO·NASDAQ

$1.48

+0.0000%

HealthcareBiotechnology

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.88M

EPS-0.3300

P/E Ratio-4.04

Earnings Date05/12/2026

7.34M

Assets

454%

3Y+14965.0%

5Y+13248.0%

10Y+13248.0%

1.43M

Total Liabilities

110%

3Y+45.0%

5Y+934.0%

10Y+934.0%

5.91M

Total Equity

820%

3Y-731.0%

5Y-7213.0%

10Y-7213.0%

Telomir Pharmaceuticals, Inc. Common Stock Funding & Solvency Profile

TELO · NASDAQ

Current Assets

Cash & Cash Equivalents7.29M

Net Receivables0.00

Inventory0.00

Other Current Assets54.69K

Total Current Assets7 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets0

Total Assets

7.34M

Financial Health Analysis

Current Ratio

5.14x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.24x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

6 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

100% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Telomir Pharmaceuticals, Inc. Common Stock Balance Sheet

TELO • NASDAQ

Telomir Pharmaceuticals, Inc. Common Stock Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	7.3M	1.3M	1.2K	1.4K	0.0
Cash & Short-Term Investments	7.3M	1.3M	1.2K	1.4K	0.0
Net Receivables	0.0	0.0	130K	0.0	0.0
Other Receivables	0.0	0.0	130K	0.0	0.0
Prepaids	0.0	57.9K	713.0	0.0	0.0
Other Current Assets	54.7K	0.0	303.3K	47.3K	0.0
Total Current Assets	7.3M	1.3M	435.2K	48.7K	0.0
NON-CURRENT ASSETS
Long-Term Investments	0.0	0.0	0.0	0.0	55K
Other Non-Current Assets	0.0	0.0	4.3M	0.0	0.0
Total Non-Current Assets	0.0	0.0	4.3M	0.0	55K
Total Assets	7.3M	1.3M	4.8M	48.7K	55K
LIABILITIES
CURRENT LIABILITIES
Total Payables	0.0	587.5K	707.2K	404.2K	18.7K
Accounts Payable	0.0	587.5K	707.2K	404.2K	18.7K
Short Term Debt	0.0	93.4K	101K	581.8K	0.0
Other Current Liabilities	1.4M	0.0	527.4K	0.0	119.4K
Total Current Liabilities	1.4M	681K	1.3M	986K	138.1K
NON-CURRENT LIABILITIES
Total Liabilities	1.4M	681K	1.3M	986K	138.1K
SHAREHOLDERS' EQUITY
Additional Paid-In Capital	0.0	31.2M	17.5M	55K	55K
Retained Earnings	-41M	-30.6M	-14.1M	-992.3K	-138.1K
Other Total Stockholders' Equity	46.9M	0.0	0.0	0.0	0.0
Total Stockholders' Equity	5.9M	643K	3.4M	-937.3K	-83.1K
Total Equity	5.9M	643K	3.4M	-937.3K	-83.1K
SUMMARY
Total Liabilities & Equity	7.3M	1.3M	4.8M	48.7K	55K
Total Investments	0.0	0.0	0.0	0.0	55K
Total Debt	0.0	93.4K	101K	581.8K	0.0
Net Debt	-7.3M	-1.2M	99.8K	580.4K	0.0
Shares Outstanding	32,796,652	32,796,652	32,796,652	32,796,652	32,796,652

SEC Filings

TELO - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	March 31, 2026	March 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 31, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 23, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 17, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 17, 2026	February 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 05, 2026	February 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 08, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 05, 2026	January 05, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 22, 2025	December 17, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 17, 2025	December 17, 2025	2025	View Filing

Showing 1 to 10 of 67 filings

Related Guides

Blog Categories

Continue your TELO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.